Navigation Links
Human Genome Sciences Announces Second Quarter 2008 Financial Results and Key Developments
Date:7/30/2008

in listening to the live webcast should log on before the conference call begins to download any software required. Both the audio replay and the archive of the conference call webcast will remain available for several days.

ABOUT HUMAN GENOME SCIENCES

The mission of HGS is to apply great science and great medicine to bring innovative drugs to patients with unmet medical needs.

The HGS clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. The Company's primary focus is rapid progress toward the commercialization of its two key lead drugs, Albuferon(R) (albinterferon alfa-2b) for hepatitis C and LymphoStat-B(R) (belimumab) for lupus. Phase 3 clinical trials of both drugs are ongoing.

ABthrax(TM) (raxibacumab) is in late-stage development for the treatment of inhalation anthrax, and the Company is on track to begin the delivery in fall 2008 of 20,000 doses of ABthrax to the Strategic National Stockpile under a contract entered into with the U.S. Government in June 2006. HGS also has three drugs in clinical development for the treatment of cancer, including two TRAIL receptor antibodies and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. In addition, HGS has substantial financial rights to three products in the GSK clinical development pipeline.

For more information about HGS, please visit the Company's web site at http://www.hgsi.com. Health professionals and patients interested in clinical trials of HGS products may inquire via e-mail to clinical_trials@hgsi.com or by calling HGS at (301) 610-5790, extension 3550.

HGS, Human Genome Sciences, ABthrax, Albuferon and LymphoStat-B are trademarks of Human Genome Sciences, Inc.

SAFE HARBOR STATEMENT

This announcement contains forward-looking statements within the me
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Human Genome Sciences Appoints David P. Southwell to its Board of Directors
2. Human Genome Sciences to Sponsor Conference Call to Discuss Second Quarter 2008 Financial Results
3. New map IDs the core of the human brain
4. BioTime, Inc. and Embryome Sciences, Inc. Sign Agreement With International Stem Cell Corporation to Provide Unique Human Stem Cell Lines for Research Use
5. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
6. China Biologic Products Announces SFDA Approval for the Production and Sale of Human Albumin 12.5g/vial (25%, 50 ml)
7. MAP Pharmaceuticals Appoints Marco Rosa Vice President of Human Resources
8. Gen-Probe Launches in Europe CE-Marked APTIMA(R) HPV Assay for Detection of Human Papillomavirus
9. Robots moving closer to humans
10. Highest Replikin Concentrations and Cyclical Behavior Related to Human Mortality Are Found in Malaria Trypanosomes
11. Human Genome Sciences Names Kevin P. McRaith Vice President, Hepatology Franchise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... 2014 On January, 14, 2015, ... Washington D.C. science community to the UMBC campus for ... by the Protein Society, will take place from 9 ... 312. Through discussion, presentations and workshops, the free ... proteins, their role in the industry and the future ...
(Date:11/26/2014)... Whitehouse Laboratories is pleased to ... County (New Jersey) Chamber of Commerce as a ... organization in the North Jersey area, offers Whitehouse ... key clients in the pharmaceutical and biotechnology areas ... Membership enables Whitehouse Laboratories a higher level of ...
(Date:11/26/2014)... ADDISON, TX (PRWEB) November 25, 2014 ... age-defying skincare products, earned three prestigious MarCom Awards for ... , Nerium received a Platinum MarCom Award, the organization’s ... Real Event in St. Louis held in April of ... for more than 14,000 attendees. Additionally, Nerium was awarded ...
Breaking Biology Technology:Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 2Whitehouse Laboratories Joins Morris County Chamber of Commerce 3Nerium International™ Wins One Platinum, Two Gold MarCom Awards 2
... Calif., Feb. 14 Onyx,Pharmaceuticals, Inc. (Nasdaq: ONXX ... management to discuss fourth quarter and full year 2007,financial ... 19,2008, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific ... December 31, 2007 will be released,earlier that day., ...
... for Open DICOM Standard DR and Data Management Systems Spurs ... Forty-Five Percent Growth for ... Systems, a,leading developer of digital radiography (DR), PACS (Picture Archiving ... announced the company,s revenues grew 45 percent,to surpass $35 million ...
... Developing and ... SOLANA BEACH, Calif., Feb. 14 ZyGEM Corp. Ltd., ... and detection and other life sciences applications, today,announced the appointment ... Clinical Advisory Board. Dr. Ahn and the new advisory board ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast 2Eklin Medical Reports Record Revenues for 2007 2Eklin Medical Reports Record Revenues for 2007 3ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 2ZyGEM Appoints Leading Biotechnology Expert to Head Clinical Advisory Board 3
(Date:11/3/2014)... Research and Markets has announced the addition of ... Companies" to their offering. This report ... already started to play an important role in the practice ... fashioned bone marrow transplants. Role of cells in drug discovery ... part of medical practice. Stem cells are discussed ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... Physics World , James Dacey explores the ways in ... take their innovations from the lab into the commercial ... all start-up companies as they move from prototype to ... main factors: physics-based inventions are usually far from market-ready ... be a lot more complicated than had been originally ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
... back Cedric Humes was able to play against Boston ... in part, to a prototype composite brace designed for ... professor of materials science and engineering in the College ... Goforth, Virginia Tech's director of athletic training shortly after ...
... More women choosing C-sections when no medical necessity exists ... rates;Nevada, Washington, Florida increase most , The number ... section (C-section) rose by 36.6 percent from 2001 to ... the leading provider of independent healthcare ratings. The study ...
... Kirkwood of the University of Newcastle, there is no single ... get food, produce offspring and survive danger - not to ... body slowly breaks down. , This topic was of great ... genomics and disease" taking place in Oslo, Norway. Thomas ...
Cached Biology News:Virginia Tech football player uses prototype cast 2'Patient-choice' C-section rate rises 36%: HealthGrades study 2'Patient-choice' C-section rate rises 36%: HealthGrades study 3
... effect inhibition assays, also known as CPE and ... supernatents; serum from PK studies and delivery formulations. ... as the quantity of interferon required per milliliter ... by 50%. All standards used in ...
Request Info...
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
Biology Products: